Vertex Pharmaceuticals Incorporated

Research & Development
11010 Torreyana Road
San Diego
California
92121
United States

Tel: 858-404-6600
Fax: 858-404-6726

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain.
Vertex Pharmaceuticals is an Equal Opportunity Employer.
Key Contacts Media: mediainfo@vrtx.com Investors: investorinfo@vrtx.com Patient Inquiries: clinical_trials@vrtx.com

This div will be replaced

184 articles about Vertex Pharmaceuticals Incorporated

Vertex Awards $400,000 in Scholarships to People Living with Cystic Fibrosis and Their Immediate Family Members

5/1/2018

Vertex Pharmaceuticals Incorporated announced the recipients of scholarships as part of its second All in for CF Scholarship program.
Vertex Reports First-Quarter 2018 Financial Results

4/26/2018

Vertex Pharmaceuticals Incorporated reported consolidated financial results for the first quarter ended March 31, 2018.
Vertex Initiates Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis

4/26/2018

Vertex Pharmaceuticals Incorporated announced that it is initiating two Phase 3 studies of VX-445.
Q-State Biosciences and Vertex Pharmaceuticals Enter into Multi-Year Drug Discovery Collaboration

4/4/2018

Q-State Biosciences, Inc. today announced that the company has entered into a strategic collaboration with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) to discover drugs using Q-State’s novel Optopatch™ platform.
Fading Vertex Pharmaceuticals (CA) Drug Incivek was Also Fastest to Become a Blockbuster

11/1/2013
GlobalDataWith the Threat of Competition Looming, Vertex Pharmaceuticals (MA) Boasts of Promising New HCV Therapy

8/2/2012
Vertex Pharmaceuticals (CA): Phase 3 STRIVE Study of VX-770 Showed Durable Improvements in Lung Function (FEV1) and Other Measures of Disease Among People With a Specific Type of Cystic Fibrosis

6/10/2011
Vertex Pharmaceuticals (CA) Plans to Provide Access to Potential CF Therapy VX-770 for Patients with Critical Medical Need

6/10/2011
Vertex Pharmaceuticals (CA) Announces Webcasts of its Presentations at Two Investor Conferences

5/27/2011
Vertex Pharmaceuticals (CA) Announces Webcasts of its Presentations at Two Investor Conferences

5/2/2011
Vertex Pharmaceuticals (CA) Stock Trading Halted Amid FDA Review

4/28/2011
Vertex Pharmaceuticals (CA) Rises After FDA Staff Says Hepatitis C Drug Is Effective

4/26/2011
Vertex Pharmaceuticals (CA) Announces the Date of its Full Year 2010 Financial Results Conference Call and Webcast

1/24/2011
Vertex Pharmaceuticals (CA) Announces Key Business Objectives To Support Planned Launch of Telaprevir in Hepatitis C and Continued Progress in Other Serious Diseases

1/10/2011
Vertex Pharmaceuticals (CA) Announces Webcast of its Presentation at the 29th Annual J.P. Morgan Healthcare Conference

1/6/2011
Vertex Pharmaceuticals (CA) Ends Part Of Telaprevir Phase II Study For Hepatitis C

12/22/2010
"Warehoused" Hepatitis C Patients May Boost Merck & Co., Inc., Johnson & Johnson, Vertex Pharmaceuticals (CA)

4/19/2010
Vertex Pharmaceuticals (CA) Announces the Date of its First Quarter 2010 Financial Results Conference Call and Webcast

4/6/2010
Vertex Pharmaceuticals (CA) Reviews 2010 Business Priorities to Support Goal of Becoming Fully-Capable Biopharmaceutical Company

1/11/2010
Bend Research and Vertex Pharmaceuticals (CA) Enter New Scientific Collaboration Bend to Provide Novel Formulation Development and Manufacturing Services for Specific Vertex-led Projects and Clinical Trials

11/9/2009